ELVN - NASDAQ

Enliven Therapeutics, Inc.

ELVN·NASDAQ

$37.48

+4.0%

HealthcareBiotechnology

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$2.28B

EPS-1.8300

P/E Ratio-20.48

Earnings Date08/12/2026

elvn

Total Other Income Expenses Net

Last Annual Value

15.96M

3-Year CAGR

142%

5-Year CAGR

30%

10-Year CAGR

Adjust for Inflation

Enliven Therapeutics, Inc. Competitors Analysis of Total Other Income Expenses Net

ELVN · NASDAQ

Company	Total Other Income Expenses Net	CAGR 3Y	CAGR 5Y	CAGR 10Y
Enliven Therapeutics, Inc. NASDAQ:ELVN	15.96M	10.2%	273.4%	N/A
Dianthus Therapeutics, Inc. NASDAQ:DNTH	15.60M	50.0%	N/A	N/A
ORIC Pharmaceuticals, Inc. NASDAQ:ORIC	13.54M	10.3%	144.2%	N/A
Atai Beckley Inc. NASDAQ:ATAI	-560.09M	N/A	N/A	N/A
Relay Therapeutics, Inc. NASDAQ:RLAY	26.26M	-5.4%	99.7%	N/A
Inhibrx Biosciences, Inc. NASDAQ:INBX	-5.03M	N/A	N/A	N/A
Sana Biotechnology, Inc. NASDAQ:SANA	-53.21M	N/A	N/A	N/A
Nektar Therapeutics NASDAQ:NKTR	-33.44M	N/A	N/A	N/A
Precigen, Inc. NASDAQ:PGEN	-144.04M	N/A	N/A	N/A
Syndax Pharmaceuticals, Inc. NASDAQ:SNDX	-12.34M	N/A	N/A	N/A

Enliven Therapeutics, Inc. Fair Value Envelope

ELVN · NASDAQ

Our analysis suggests that ELVN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $37.48, this represents a potential HIDDEN relative to our calculated worth for Enliven Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $37.48

Related Guides

Blog Categories

Continue your ELVN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.